MedTrace Logo

Low QRS Voltages in Young Healthy Individuals and Athletes

NCT05799833 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 240

Last updated 2023-10-04

No results posted yet for this study

Summary

There is some limited evidence that reduced size of electrical complexes/traces of the heart on the electrocardiogram (ECG) may be associated with scarring in the heart muscle, which may predispose to serious life-threatening electrical abnormalities and sudden cardiac death (SCD). There is no current guidance on how young individuals and athletes with reduced ECG traces should be managed. Therefore, correct interpretation of this ECG finding is crucial for identifying athletes with disease and at risk of SCD. Some athletes experience SCD despite normal standard cardiac tests. The investigators, therefore, propose to study young healthy individuals and young athletes using cardiovascular MRI, cardiopulmonary exercise testing, 24 hour ECG monitoring and genetic analysis to determine the significance of reduced ECG traces and possibly revise current international sports recommendations.

Conditions

  • Sudden Cardiac Death
  • Sudden Cardiac Arrest
  • Sudden Cardiac Death Due to Cardiac Arrhythmia
  • Arrhythmogenic Right Ventricular Cardiomyopathy
  • Arrhythmogenic Left Ventricular Cardiomyopathy
  • Dilated Cardiomyopathy

Interventions

DIAGNOSTIC_TEST

Cardiovascular magnetic resonance scan - 3T scanner (Siemens Vida)

4 study groups will undergo testing with 12-lead ECG, blood test, cardiac MRI, cardiopulmonary exercise testing and 24 hour holter monitor. A subgroup (N=50 anticipated) will undergo genetic testing.

Sponsors & Collaborators

  • Royal Brompton & Harefield NHS Foundation Trust

    collaborator OTHER

  • Cardiac Risk in the Young

    collaborator OTHER

  • St George's, University of London

    collaborator OTHER

  • Imperial College London

    lead OTHER

Principal Investigators

  • Sabiha Gati, MBBS · Royal Brompton & Harefield NHS Foundation Trust

Eligibility

Min Age
17 Years
Max Age
35 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-10-09
Primary Completion
2025-05-01
Completion
2025-11-01

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05799833 on ClinicalTrials.gov